| Zacks Company Profile for Theratechnologies Inc. (THTX : NSDQ) |
|
|
| |
| • Company Description |
| Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada.
Number of Employees: 94 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $2.30 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 129,492 shares |
| Shares Outstanding: 45.98 (millions) |
| Market Capitalization: $105.75 (millions) |
| Beta: 0.55 |
| 52 Week High: $3.13 |
| 52 Week Low: $1.12 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-11.88% |
-15.11% |
| 12 Week |
48.39% |
19.29% |
| Year To Date |
27.07% |
20.58% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
2015 Peel Street 11th Floor
-
MONTREAL,A8 H3A 1T8
CAN |
ph: 438-315-6607
fax: 514-331-9691 |
ir@theratech.com |
http://www.theratech.com |
|
|
| |
| • General Corporate Information |
Officers
Paul Levesque - President and Chief Executive Officer
Philippe Dubuc - Senior Vice President and Chief Financial Officer
Jocelyn Lafond - General Counsel and Corporate Secretary
Alain Trudeau - Director
Dawn Svoronos - Director
|
|
Peer Information
Theratechnologies Inc. (CORR.)
Theratechnologies Inc. (RSPI)
Theratechnologies Inc. (CGXP)
Theratechnologies Inc. (BGEN)
Theratechnologies Inc. (GTBP)
Theratechnologies Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 88338H704
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: November
Last Reported Quarter: 02/01/25
Next Expected EPS Date: 07/09/25
|
|
Share - Related Items
Shares Outstanding: 45.98
Most Recent Split Date: 7.00 (0.25:1)
Beta: 0.55
Market Capitalization: $105.75 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.17 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/09/25 |
|
|
|
| |
